Louise Proulx

Louise Proulx has held various positions in the biopharmaceutical industry. Most recently, she was co-founder of Therillia Development Company and a partner at Sanderling until the end of 2018. Dr. Proulx served as Vice President of Product Development at BioChem Pharma and ViroChem Pharma during the acquisition of these two companies. After the acquisition of ViroChem by Vertex Pharmaceuticals, she became Site Manager of Vertex Canada. She currently sits on the Board of Directors of the Research Institute of the McGill University Health Center, the Quebec Blue Cross, the Quebec Consortium for Drug Discovery (CQDM) and Catalis Quebec. Ms. Proulx holds a doctorate from Laval University and pursued postdoctoral studies at the Karolinska Institute in Stockholm.